CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 43 enrolled
Drug / intervention
Renewaldevice
Likely dose
Renewal CRT-D device implantationAI-extracted
Key inclusion· 6
  • ✓Symptoms of heart failure
  • ✓Left ventricular dysfunction
  • ✓Ventricular dyssynchrony
  • ✓Age 18 years or older and able to provide informed consent
Key exclusion· 6
  • ✕Atrial fibrillation
  • ✕Life expectancy less than 6 months due to other medical conditions
  • ✕Mechanical tricuspid prosthesis
  • ✕Hypertrophic obstructive cardiomyopathy (HOCM)

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00180323
NCT00180323N/ACompleted
CompareCT.gov

ACC - Atrial Contribution to CRT

Boston Scientific Corporation·interventional·Posted Sep 16, 2005·Updated Feb 11, 2021

In Brief

A clinical study evaluating Renewal for Dilated Cardiomyopathy. Completed, enrolled 43 participants across 1 site.

Detailed Summary

This prospective study will evaluate in patients, fulfilling implant criteria for Cardiac Resynchronisation Therapy (CRT) implant, the optimal atrial contribution to the resynchronised ventricles in the event of right atrial pacing.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDilated Cardiomyopathy
CountriesDenmark
Collaborators--

Timeline

N/ACompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 16, 2005
Enrollment StartNov 1, 2004
Primary CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 20.8 years ago

Interventions

Renewaldevice

Renewal is a CRT-D device for cardiac resynchronization therapy